A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma

Lomeguatrib, an O(6)-methylguanine-DNA methyltransferase inactivator, was evaluated in an extended dosing regimen with temozolomide, designed according to pharmacodynamic data from previous studies. Patients with unresectable stage 3 or 4 cutaneous or unknown primary melanoma metastases were treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Kefford, R F, Thomas, N P B, Corrie, P G, Palmer, C, Abdi, E, Kotasek, D, Beith, J, Ranson, M, Mortimer, P, Watson, A J, Margison, G P, Middleton, M R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676549/
https://www.ncbi.nlm.nih.gov/pubmed/19367282
http://dx.doi.org/10.1038/sj.bjc.6605016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676549/
https://www.ncbi.nlm.nih.gov/pubmed/19367282
http://dx.doi.org/10.1038/sj.bjc.6605016

Ejemplares similares